ITIL-168

BIOLOGICAL2 trials

Sponsors

Instil Bio

Conditions

Advanced Cutaneous MelanomaCervical CancerHead and Neck Squamous Cell CarcinomaNon-small Cell Lung Cancer

Phase 1

ITIL-168 in Advanced Solid Tumors

WithdrawnNCT05393635

Instil BioCervical Cancer, Head and Neck Squamous Cell Carcinoma, Non-small Cell Lung Cancer

Start: 2022-08-31End: 2022-12-08Updated: 2022-12-20

Phase 2

ITIL-168 in Advanced Melanoma

TerminatedNCT05050006

Instil BioAdvanced Cutaneous Melanoma

Start: 2021-10-07End: 2023-02-27Updated: 2024-04-16

Related Papers

781 DELTA-2: A phase 1, open-label, multicenter study of ITIL-168, an autologous tumor-infiltrating lymphocyte (TIL) cell therapy, with pembrolizumab in patients with advanced solid tumors

Regular and Young Investigator Award Abstracts2022-11-01

787 DELTA-1: a global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma

Regular and Young Investigator Award Abstracts2022-11-01

DELTA-1: A global, multicenter, phase 2 study of ITIL-168, an unrestricted autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in adult patients with advanced cutaneous melanoma.

Journal of Clinical Oncology2022-06-012 citations